Question 4: Has the disease relapsed or progressed since the date of last report?
Report if the recipient had a hematologic or clinical relapse at any time during the reporting period. Progression is defined as an increase in WBC and/or organomegaly or transformation to AML. Relapse is defined as the reappearance of disease characteristics after a complete remission. Do not report relapse or progression for the reappearance of molecular or cytogenetic abnormalities associated with the patient’s disease in the absence of clinical evidence of disease.
If no assessments were consistent with relapse or progression during the reporting period, indicate “no” and continue with question 11.
Question 5: Date of disease relapse/progression
Report the date of the assessment consistent with relapse or progression. If relapse or progression was identified by hematologic assessment, report the date the specimen was collected.
Questions 6-10: Specify site(s) of disease relapse/progression
Indicate “yes” or “no” for each site specified in questions 6-9. Do not leave any responses blank. Specify only the sites of clinical or hematologic disease; cytogenetic and molecular evidence of disease does not need to be specified. If “yes” is indicated for “other site,” specify the site in question 10. At least one of questions 6-9 must be answered “yes.”
Section Updates:
| Question Number | Date of Change | Add/Remove/Modify | Description | Reasoning (If applicable) |
|---|---|---|---|---|
| . | . | . | . | . |
Need more help with this?
Don’t hesitate to contact us here.